ABCB1 and colorectal carcinoma: Nevertheless, MDR1 is believed to play a minor role in CRC resistance to pharmacological treatment based on 5-FU, platinum derivatives, irinotecan, and its active metabolites because these drugs are not transported by MDR1 [189,190].